From B to C: The Advent of CYOD


BYOD has been a buzzword in the clinical trial space since mProve Health got started in 2010. We have seen the movement go from risky and heavily-hyped to a conservatively accepted. From our start in ePRO, we’ve been driving the BYOD bandwagon. Now, though, we want to pull over and ask for directions. That stopover is CYOD.


Forward Together on the Hero’s Journey

mProve Health recently had the privilege of adding “artistic services” to its accomplishments! We were pleased that Eli Lilly and Company invited us to take part in The Hero’s Journey art project, and we submitted our contribution last week.

Hero's Journey mProve Brick

Embracing the trend of patient centricity, Lilly launched The Hero’s Journey as a collaborative, installation-style artwork that celebrates the contributions of clinical trial patients. In the literary tradition, the Hero’s Journey is a classic narrative of the protagonist battling various obstacles, always for the greater good. The hero doesn’t always make it, but their work makes life easier for those who come after them.

Trial subjects are asked to donate their time and bodies, sometimes as healthy volunteers and sometimes as a last chance for treatment. As we understand it, the art project is an attempt to bring the patient contribution out of the shadow of leading drug developers and researchers. It reminds us that patient participants in a trial are perhaps the most important contributors to modern pharmacology.

Artist John Magnan was brought on to design the piece for Lilly. Using wood, he created three teardrop structures, which will collectively hold 1,000 brick-sized wooden blocks. Lilly shipped these bricks to all sorts of people involved in clinical research, from their own employees to CROs to vendors like us. (When we were first asked to contribute, we worried that Lilly was using real bricks and felt for the postal worker who had to carry them all around.) We were all encouraged to design the brick in our interpretation of the Hero’s Journey theme, using whatever media we had available.

We see our products as a signposting tool for patients already on a treatment journey. The decisions about how to seek treatment and whether to engage in clinical trials are theirs alone–as they should be. What we always aim to do is to provide additional support so that the patients’ decisions are, perhaps, a little easier to make.

We are also excited that the patient centricity trend is pushing pharma towards giving patients a stronger, louder voice in trial design and in their individual treatment. One of the most wonderful things is seeing how a group of patients, by consenting to become data points in the study results, collect themselves into an impactful whole. One datum by itself is usually insignificant, but data compounded push lifesaving treatments further towards the market.

Our Trial Guide app uses path and guidepost symbolism already, so starting with that imagery was an easy decision for the informal mProve brick committee. It was important to us that each patient be represented, and that not all patients be shown as following the same journey; some are on the road from the beginning, while others wander in a bit later. We chose oil paints to show each patient as a unique data point, flowing down a path toward blue skies until they become indistinguishable parts of a larger whole.

Learn more about The Hero’s Journey here: We encourage anyone who has the opportunity to go see it, and to look for the mProve brick!

One App to Unite Them All: Unified Patient Engagement

On October 21st, I was honored to present at the 2016 Bioinformatics & Computational Biosciences Festival, Virtual Clinical Trials: Modernizing Comparative Studies, hosted by the National Institute of Allergy and Infectious Diseases. The event focused on the emerging model of less site-centric studies, and how tech is helping enable this new model. I spoke on an emerging issue resulting from too much of a good thing: patient engagement and retention services. As various patient engagement systems and vendors abound, clinical trial patients will need a central engagement hub to access all aspects of their study. We think it’s important to design that platform now.

Jeff Lee delivers a presentation on uniting the patient engagement experience.

Jeff Lee speaks at 2016 Bioinformatics & Computational Biosciences Festival, Virtual Clinical Trials: Modernizing Comparative Studies.


Patient Centricity Takes Center Stage at dPharm ’16

mProve at dPharm' 16

(WASHINGTON, DC) Clinical research innovators came together from across the country at the 6th annual DPharm: Disruptive Innovations to Advance Clinical Trials. We joined attendees from across the industry to celebrate last year’s achievements, discuss industry missteps, and investigate the future of clinical trials. This year, many speakers focused on the patient experience as the core of the clinical trial. We look forward to seeing the results of giving patients a seat at the table.

mProve Health sees patient centricity as a core value, because designing our products around an excellent user experience has been a matter of course since our days in the commercial sector. Again and again, we see the benefits of enthusiastically engaging the patients to improve our own product design. How much can be accomplished now that researchers are doing the same?


Breaking (into) BYOD: New Data from Industry Leadership


(WASHINGTON, DC) BYOD supporters are in luck: If you want to see the bring-your-own-device movement get better, there is new data showing that industry leaders aren’t as opposed to BYOD as you may think.

Applied Clinical Trials recently published a study that surveyed lead eCOA providers (and those related) on their opinions. mProve Founder and CEO Jeff Lee coauthored the article with Bill Byrom of ICON and other thought leaders within ICON and Medidata.

The authors lead a growing effort to push the BYOD concept forward and begin using it in mainstream clinical trials. The movement has been stalled for years at what Lee calls “the BYOD stalemate”: the FDA cannot issue any statements on the validity of BYOD-sourced data without seeing drug studies that use it; conversely, pharma companies are unwilling to risk the success of their clinical trials on a data collection method that the FDA hasn’t rubber-stamped. Byrom and Lee are some of the BYOD proponents trying to break through the red tape.

To shed light on the industry climate, the authors report on a survey taken by several dozen professionals at CROs, eCOA vendors, and biopharmaceutical companies. The survey asked a series of questions about some of the doubts surrounding BYOD: that subjects may lose or change their device, that the data collected may not be private, that site staff would be burdened, that the patient would delete or corrupt the app, etc. (more…)

Page 1 of 212